You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBoceprevir
Accession NumberDB08873
TypeSmall Molecule
GroupsApproved
Description

Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011.

Structure
Thumb
Synonyms
SCH 503034
Victrelis
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Victreliscapsule200 mg/1oralMerck Sharp & Dohme Corp.2011-05-13Not applicableUs
Victreliscapsule200 mgoralMerck Canada Inc2011-08-02Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Victrelis TripleMerck Canada Inc
SaltsNot Available
Categories
UNII89BT58KELH
CAS number394730-60-0
WeightAverage: 519.6767
Monoisotopic: 519.342069575
Chemical FormulaC27H45N5O5
InChI KeyInChIKey=LHHCSNFAOIFYRV-DOVBMPENSA-N
InChI
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
IUPAC Name
3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
SMILES
[H][C@]12CN([[email protected]](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentHybrid peptides
Alternative Parents
Substituents
  • Hybrid peptide
  • N-carbamoyl-alpha-amino acid or derivatives
  • Alpha-amino acid amide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • N-acyl-piperidine
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-acylpyrrolidine
  • Fatty acyl
  • Piperidine
  • Fatty amide
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Alpha-aminoketone
  • Urea
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Primary carboxylic acid amide
  • Ketone
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed.
PharmacodynamicsTelaprevir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.
Mechanism of actionBoceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication.
Related Articles
AbsorptionFood increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food. Tmax = 2 hours; Time to steady state, three times a day dosing = 1 day; Cmax, 400 mg single dose, healthy subject = 557 ng/mL; AUC ∞, healthy subject = 2020 ng · h/mL;
Volume of distribution

~722 L

Protein binding~75%
Metabolism

Hepatically metabolized by the aldo-ketoreductase pathway into inactive metabolites via reduction. To a lesser extent, CYP3A4 and CYP3A5 is also involved in the metabolism of boceprevir (oxidative process).

Route of eliminationRemoved via feces (79%) and urine (9%) which suggest some degree of hepatic excretion.
Half lifeMean plasma half-life = 3.4 hours
Clearance

Mean total body clearance (Cl/F) = 161 L/h

ToxicityNot Available
Affected organisms
  • Hepatitis C virus, RSV and other RNA/DNA viruses
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6781
Blood Brain Barrier-0.8805
Caco-2 permeable-0.6532
P-glycoprotein substrateSubstrate0.8394
P-glycoprotein inhibitor IInhibitor0.671
P-glycoprotein inhibitor IIInhibitor0.6377
Renal organic cation transporterNon-inhibitor0.8188
CYP450 2C9 substrateNon-substrate0.7965
CYP450 2D6 substrateNon-substrate0.7996
CYP450 3A4 substrateSubstrate0.621
CYP450 1A2 substrateNon-inhibitor0.7987
CYP450 2C9 inhibitorNon-inhibitor0.7265
CYP450 2D6 inhibitorNon-inhibitor0.87
CYP450 2C19 inhibitorNon-inhibitor0.6908
CYP450 3A4 inhibitorNon-inhibitor0.9659
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8434
Ames testNon AMES toxic0.662
CarcinogenicityNon-carcinogens0.8555
BiodegradationReady biodegradable0.5913
Rat acute toxicity2.6263 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9828
hERG inhibition (predictor II)Non-inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral200 mg/1
Capsuleoral200 mg
Capsule; powder for solutionoral; subcutaneous
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7772178 No2007-11-112027-11-11Us
US8119602 No2007-03-172027-03-17Us
USRE43298 No2002-02-222022-02-22Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0234 mg/mLALOGPS
logP1.93ALOGPS
logP1.78ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)12.44ChemAxon
pKa (Strongest Basic)-0.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.7 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity138.2 m3·mol-1ChemAxon
Polarizability56.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

James Lalonde, Tao Li, Jack Liang, Benjamin Mijts, Roger Sheldon, George S.K. Wong, Aleksey Zaks, “Substantially Stereomerically Pure Fused Bicyclic Proline Compounds and Processes for Preparing Boceprevir.” U.S. Patent US20120289709, issued November 15, 2012.

US20120289709
General References
  1. Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245 ]
  2. Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000. [PubMed:22799589 ]
  3. Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10. [PubMed:22506260 ]
External Links
ATC CodesJ05AE12
AHFS Codes
  • 8:18.40
PDB EntriesNot Available
FDA labelDownload (710 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Boceprevir.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Boceprevir.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Boceprevir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Boceprevir.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Boceprevir.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Boceprevir.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Boceprevir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Boceprevir.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Boceprevir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Boceprevir.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Boceprevir.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Boceprevir.
BatimastatThe serum concentration of Batimastat can be decreased when it is combined with Boceprevir.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Boceprevir.
BepridilThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.
BexaroteneThe serum concentration of Boceprevir can be decreased when it is combined with Bexarotene.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Boceprevir can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Boceprevir.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Boceprevir.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Boceprevir.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Boceprevir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Boceprevir.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Boceprevir.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Boceprevir.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Boceprevir.
CarbamazepineThe serum concentration of Boceprevir can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Boceprevir.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Boceprevir.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Boceprevir.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Boceprevir.
ClarithromycinThe serum concentration of Boceprevir can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Boceprevir can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Boceprevir.
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Boceprevir.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Boceprevir.
CyclosporineThe serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.
DabrafenibThe serum concentration of Boceprevir can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Boceprevir.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Boceprevir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Boceprevir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Boceprevir.
DeferasiroxThe serum concentration of Boceprevir can be decreased when it is combined with Deferasirox.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Boceprevir.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Boceprevir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Boceprevir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Boceprevir.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Boceprevir.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Boceprevir.
DoxazosinThe serum concentration of Doxazosin can be increased when it is combined with Boceprevir.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Boceprevir.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Boceprevir.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Boceprevir.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Boceprevir.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Boceprevir.
EfavirenzThe serum concentration of Boceprevir can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Boceprevir.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Boceprevir.
EnzalutamideThe serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Boceprevir.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Boceprevir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Boceprevir.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Boceprevir.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Boceprevir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Boceprevir.
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Boceprevir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Boceprevir.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Boceprevir.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Boceprevir.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Boceprevir.
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Boceprevir.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Boceprevir.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Boceprevir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Boceprevir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Boceprevir.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Boceprevir.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Boceprevir.
FosphenytoinThe serum concentration of Boceprevir can be decreased when it is combined with Fosphenytoin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Boceprevir.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Boceprevir.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Boceprevir.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Boceprevir.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Boceprevir.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Boceprevir resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Boceprevir.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Boceprevir.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Boceprevir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Boceprevir.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Boceprevir.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Boceprevir.
IsoflurophateThe serum concentration of Isoflurophate can be decreased when it is combined with Boceprevir.
ItraconazoleThe serum concentration of Boceprevir can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Boceprevir.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Boceprevir.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Boceprevir.
KetoconazoleThe serum concentration of Boceprevir can be increased when it is combined with Ketoconazole.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Boceprevir.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Boceprevir.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Boceprevir.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Boceprevir.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Boceprevir.
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Boceprevir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Boceprevir.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Boceprevir.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Boceprevir.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Boceprevir.
MacitentanThe serum concentration of MACITENTAN can be increased when it is combined with Boceprevir.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Boceprevir.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone Acetate can be increased when it is combined with Boceprevir.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Boceprevir.
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Boceprevir.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Boceprevir.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Boceprevir.
MitotaneThe serum concentration of Boceprevir can be decreased when it is combined with Mitotane.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Boceprevir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Boceprevir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Boceprevir.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Boceprevir.
NorethisteroneThe serum concentration of Norethindrone can be increased when it is combined with Boceprevir.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Boceprevir.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Boceprevir.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Boceprevir.
OxycodoneThe risk or severity of adverse effects can be increased when Boceprevir is combined with Oxycodone.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Boceprevir.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Boceprevir.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Boceprevir.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Boceprevir.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Boceprevir.
PhenobarbitalThe serum concentration of Boceprevir can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Boceprevir can be decreased when it is combined with Phenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Boceprevir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Boceprevir.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Boceprevir.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Boceprevir.
PosaconazoleThe serum concentration of Boceprevir can be increased when it is combined with Posaconazole.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Boceprevir.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Boceprevir resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Boceprevir.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Boceprevir.
PrimidoneThe serum concentration of Boceprevir can be decreased when it is combined with Primidone.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Boceprevir.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Boceprevir.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Boceprevir.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Boceprevir.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Boceprevir.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Boceprevir.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Boceprevir.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Boceprevir.
RifabutinThe serum concentration of Boceprevir can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Boceprevir can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Boceprevir can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Boceprevir.
RitonavirThe serum concentration of Boceprevir can be decreased when it is combined with Ritonavir.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Boceprevir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Boceprevir.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Boceprevir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Boceprevir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Boceprevir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Boceprevir.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Boceprevir.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Boceprevir.
SiltuximabThe serum concentration of Boceprevir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Boceprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Boceprevir.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Boceprevir.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Boceprevir.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Boceprevir.
St. John's WortThe serum concentration of Boceprevir can be decreased when it is combined with St. John's Wort.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Boceprevir.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Boceprevir.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Boceprevir.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Boceprevir.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Boceprevir.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Boceprevir.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Boceprevir resulting in a loss in efficacy.
TipranavirThe serum concentration of Boceprevir can be decreased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Boceprevir.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Boceprevir.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Boceprevir.
ToremifeneThe risk or severity of adverse effects can be increased when Boceprevir is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Boceprevir.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Boceprevir.
Trastuzumab emtansineThe serum concentration of the active metabolites of ado-trastuzumab emtansine can be increased when ado-trastuzumab emtansine is used in combination with Boceprevir.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Boceprevir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Boceprevir.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Boceprevir.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Boceprevir.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Boceprevir.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Boceprevir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Boceprevir.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Boceprevir.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Boceprevir.
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Boceprevir.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Boceprevir.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Boceprevir.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir.
Food Interactions
  • Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals.

Targets

Kind
Protein
Organism
Hepatitis C virus
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type peptidase activity
Specific Function:
Not Available
Gene Name:
NS3/4A
Uniprot ID:
B0B3C9
Molecular Weight:
72789.28 Da
References
  1. Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA: Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013 Jul 19;8(7):1469-78. doi: 10.1021/cb400100g. Epub 2013 May 1. [PubMed:23594083 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [PubMed:23140245 ]
Comments
comments powered by Disqus
Drug created on May 11, 2013 22:45 / Updated on July 30, 2016 01:53